NCT05973630View on ClinicalTrials.gov

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

January 31, 2031

Conditions
LGMD2C
Interventions
BIOLOGICAL

ATA-200

single intravenous infusion

Trial Locations (3)

32610

RECRUITING

Child Health Research Institute, Gainesville

Unknown

NOT_YET_RECRUITING

Hopital Trousseau, Paris

NOT_YET_RECRUITING

Ospedale Maggiore Policlinico, Milan

Sponsors
All Listed Sponsors
lead

Atamyo Therapeutics

INDUSTRY

NCT05973630 - ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 | Biotech Hunter | Biotech Hunter